ORLAAM Drug Patent Profile
✉ Email this page to a colleague
When do Orlaam patents expire, and what generic alternatives are available?
Orlaam is a drug marketed by Roxane and is included in one NDA.
The generic ingredient in ORLAAM is levomethadyl acetate hydrochloride. There is one drug master file entry for this compound. Additional details are available on the levomethadyl acetate hydrochloride profile page.
Summary for ORLAAM
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 17 |
| Clinical Trials: | 1 |
| Patent Applications: | 3,058 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | ORLAAM at DailyMed |
Recent Clinical Trials for ORLAAM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Institute on Drug Abuse (NIDA) | Phase 2 |
US Patents and Regulatory Information for ORLAAM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Roxane | ORLAAM | levomethadyl acetate hydrochloride | CONCENTRATE;ORAL | 020315-001 | Jul 9, 1993 | DISCN | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
